Pharmacyclics Llc Company Profile

✉ Email this page to a colleague

PHARMACYCLICS LLC has three approved drugs.

There are fifty-four US patents protecting PHARMACYCLICS LLC drugs.

There are three hundred and fifty patent family members on PHARMACYCLICS LLC drugs in forty-seven countries and thirty-four supplementary protection certificates in fifteen countries.

International Patents:	350
US Patents:	54
Tradenames:	1
Ingredients:	1
NDAs:	3
Patent Litigation for Pharmacyclics Llc:	See patent lawsuits for Pharmacyclics Llc

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	Yes	8,952,015*PED	⤷ Sign Up			Y	⤷ Sign Up
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-001	Feb 16, 2018		RX	Yes	No	8,735,403*PED	⤷ Sign Up			Y	⤷ Sign Up
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	Yes	9,801,881*PED	⤷ Sign Up			Y	⤷ Sign Up
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	10,125,140*PED	⤷ Sign Up			Y	⤷ Sign Up
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	10,961,251*PED	⤷ Sign Up			Y	⤷ Sign Up
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Pharmacyclics Llc	IMBRUVICA	ibrutinib	SUSPENSION;ORAL	217003-001	Aug 24, 2022		RX	Yes	Yes	11,672,803	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	70 mg	➤ Subscribe	2018-12-14
➤ Subscribe	Tablets	280 mg and 420 mg	➤ Subscribe	2018-12-14
➤ Subscribe	Tablets	140 mg and 560 mg	➤ Subscribe	2018-11-05

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2529621	13/2017	Austria	⤷ Sign Up	PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945/001-002 IDF DER FASSUNG DER ENTSCHEIDUNG DER KOMMISSION C(2015)4704 (MITTEILUNG) 20150707
2201840	233 5006-2015	Slovakia	⤷ Sign Up	PRODUCT NAME: IBRUTINIB; REGISTRATION NO/DATE: EU/1/14/945 20141023
2201840	PA2015017,C2201840	Lithuania	⤷ Sign Up	PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 20141021
2526934	122016000093	Germany	⤷ Sign Up	PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20160526
2529621	300868	Netherlands	⤷ Sign Up	PRODUCT NAME: IBRUTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/14/945 - C(2015)4704 20150707
2201840	C20150014 00145	Estonia	⤷ Sign Up	PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 23.10.2014
2526934	C20160038 00313	Estonia	⤷ Sign Up	PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 30.05.2016
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.